

Bayesian regression discontinuity design with unknown cutoff

Julia Kowalska^{*1,2}, Mark van de Wiel^{1,2}, Stéphanie van der Pas^{1,2}

¹Amsterdam UMC location VU, Epidemiology and Data Science, Amsterdam, The Netherlands

²Amsterdam Public Health, Methodology, Amsterdam, The Netherlands

June 18, 2024

Abstract

Regression discontinuity design (RDD) is a quasi-experimental approach used to estimate the causal effects of an intervention assigned based on a cutoff criterion. RDD exploits the idea that close to the cutoff units below and above are similar; hence, they can be meaningfully compared. Consequently, the causal effect can be estimated only locally at the cutoff point. This makes the cutoff point an essential element of RDD. However, especially in medical applications, the exact cutoff location may not always be disclosed to the researcher, and even when it is, the actual location may deviate from the official one. As we illustrate on the application of RDD to the HIV treatment eligibility data, estimating the causal effect at an incorrect cutoff point leads to meaningless results. Moreover, since the cutoff criterion often acts as a guideline rather than as a strict rule, the location of the cutoff may be unclear from the data. The method we present can be applied both as an estimation and validation tool in RDD. We use a Bayesian approach to incorporate prior knowledge and uncertainty about the cutoff location in the causal effect estimation. At the same time, our Bayesian model LoTTA is fitted globally to the whole data, whereas RDD is a local, boundary point estimation problem. In this work we address a natural question that arises: how to make Bayesian inference more local to render a meaningful and powerful estimate of the treatment effect?

Keywords: Regression discontinuity; Unknown cutoff; Bayesian causal inference

*Corresponding author, E-mail address: j.m.kowalska@amsterdamumc.nl

1 Introduction

The regression discontinuity design (RDD) is a quasi-experimental approach used to estimate the causal effects of an intervention assigned based on a cutoff criterion. It was applied for the first time in 1960 by Thistlethwaite & Campbell to evaluate the effect of receiving a certificate of merit on students' future academic careers.¹ Despite its increasing popularity in empirical studies, and many opportunities, RDD appears to be underutilized in medicine outside of health economics.^{2,3}

RDD corresponds to the following framework.^{4,5} First, each unit (patient) receives a *score*. The score is a pre-intervention variable, such as age or blood pressure, which often influences the intervention's outcome. Next, the score is compared to the prespecified *cutoff value*. The cutoff criterion may be the only determinant of the intervention allocation, in which case the design is called *sharp*. In the sharp design all units with scores equal or higher than the cutoff value are assigned to one type of an intervention, and all units with scores below to the other. If the compliance to the cutoff rule is imperfect, then the design is called *fuzzy*. In this scenario units with scores just above the cutoff have significantly higher chances of being assigned to the intervention than units with scores just below. Finally, for each unit outcome of interest is observed. RDD exploits the idea that (infinitesimally) close to the cutoff, units below and above are similar in terms of important characteristics; hence, they can be meaningfully compared.⁶ By estimating the treatment effect at the cutoff, the common problem of unbalanced groups is mostly avoided at the price of restricted generalizability.

We speculate that the underutilization of RDD in medicine is partially explained by the imperfect compliance to many health interventions, necessitating the less well-studied fuzzy design. A further complication appears when the cutoff cannot be disclosed to the researchers due to privacy regulations or administrative issues. For instance, this can be true for registries that collect data from many anonymized hospitals.⁷ Another example is policies' implementation dates; while they are commonly used as cutoff points,³ they cannot always be retrieved to the desired precision.⁸ In addition, attention should be drawn to a similar problem of *seemingly* known cutoffs. A commonly held assumption is that the cutoff given by an official guideline is the same point at which the treatment effect is to be estimated. However, those are not necessarily the same, as it will become apparent in our reanalysis of ART data from Hlabisa HIV Treatment and Care Programme.

Currently, the standard method of analyzing an RDD with a known cutoff is through weighted local linear regression (LLR). It is a well-studied framework that provides robust, asymptotically valid confidence intervals.⁹ Moreover, some methods were developed to estimate the location of an unknown cutoff.¹⁰ However, once the cutoff point is estimated, it is treated as known; we are not aware of any available method that allows us to include the uncertainty about its location in the final treatment effect estimation. In this paper, we present a method that aims to be both an estimation and a falsification tool for RDD's with unknown or uncertain cutoffs. By turning to the Bayesian paradigm, the uncertainty about the cutoff is included in a natural way, as part of a larger model. Furthermore, expert knowledge about the suspected cutoff location can be easily incorporated through an informative prior.

Bayesian methods have previously been designed for RDD's with a known cutoff. Geneletti et al.¹¹ fit Bayesian linear regression in a cutoff's neighborhood, which ultimately ought to be selected through expert-knowledge. The main focus is placed on the prior selection and sensitivity analysis. Chib et al.¹² also emphasize the influence of points near the cutoff, but do not discard points further away. Instead, they fit cubic splines globally with a higher density of knots in the cutoff's neighborhood selected based on the score's quantiles. Finally, Branson et al.¹³ propose

the use of a flexible nonparametric model with an exponential Gaussian process prior. Unlike the aforementioned solutions, no emphasis is put on any particular neighborhood of the cutoff. The inference is stabilized by shared covariance parameters that are estimated from the data on both sides of the cutoff. The above methods cannot be easily translated to the unknown cutoff scenario, as they require manual adjustments that depend on the cutoff location or as they are challenging to implement in an efficient way.

Thus, our main contribution is the development of a fully Bayesian approach to RDD with an unknown cutoff. To the best of our knowledge, our model (LoTTA) is the first one in the RDD literature that propagates the uncertainty of the cutoff location to the treatment effect estimation. A significant advantage of the model is that it does not require tuning or manual window selection, making it easy to apply. We also contribute a new perspective on feedback between design and analysis stages in Bayesian causal inference,^{14,15,16} as in contrast to propensity score based models, we find significant advantages towards allowing such feedback in RDD. Moreover, we introduce a novel approach to the cutoff validation in the fuzzy RD design with a presumed known cutoff. We demonstrate that the current methods may be insufficient and explain how the Bayesian model can help to fill this gap.

The paper is organized as follows. In Section 2, we introduce the notation and present the causal inference framework for RDD. In Section 3, we discuss the cutoff detection model in detail, along with comments on its implementation and its place in the wider context of causal inference. In Section 4, we explain through a real-life example the steps of the cutoff detection analysis and how the model can be used as a falsification tool. We conclude this section with a surprising finding of a cutoff located at a different point than implied by the corresponding guidelines. In Section 5, we present simulation results on the frequentist properties of the model. Finally, in Section 6, we summarize key takeaways.

2 Setup

2.1 Causal framework

In terms of causal inference we reason in the potential outcomes framework with two competing treatments.¹⁷ This framework assumes that for each unit there exist two outcomes corresponding to each treatment but we can only observe one of them - the one of the assigned treatment. Throughout the paper, we denote the potential outcomes under treatment and no treatment by $Y^{(1)}$ and $Y^{(0)}$ respectively. We focus on fuzzy RDD, so on the scenario of imperfect compliance to the cutoff rule. In a sharp design the cutoff is straightforward to detect. Consequently, as it is usual in this setting,⁴ we differentiate four subgroups of participants: always-takers (A), never-takers (N), compliers (C) and defiers (D). Always-takers and never-takers, respectively, either always or never receive the treatment regardless of their score. Compliers receive the treatment according to the cutoff rule based solely on their score, while defiers receive the opposite treatment with respect to the cutoff rule. The causal estimand of interest is the local average treatment effect τ , which in this case is the expected mean difference between $Y^{(1)}$ and $Y^{(0)}$ for compliers with scores equal to the cutoff value, see (1).

2.2 Notation

In this section we introduce the notation and some general assumptions. By X we denote the score variable that takes values in a bounded interval $\mathcal{I} = [I_1, I_2]$; by Y the outcome variable that takes values in \mathbb{R} ; by $T \in \{0, 1\}$ the binary treatment received; and by $c \in (I_1, I_2)$ the cutoff

location. Furthermore, we consider two functions: treatment probability function p and outcome function f .

Assumption 1. The treatment probability function $p: \mathcal{I} \rightarrow [0, 1]$ has precisely one discontinuity point at c , and is given by the relation

$$\mathbb{P}(T = 1|X = x) = p(x).$$

Moreover, at c the function p is right-continuous.

Assumption 2. There exists a right-continuous deterministic function f with at most one discontinuity point at c such that

$$Y|_{X=x} \sim \mathcal{N}(f(x), \sigma_x).$$

Moreover, $\mathbb{E}[Y|X = x, A]$ and $\mathbb{E}[Y|X = x, N]$ are continuous at c .

In the model we consider in Section 3, we allow the error term to depend on the score x , however not in full generality. Finally, we need the standard assumption of no defiers to identify the treatment effect τ .⁴

Assumption 3. For each unit $\mathbb{P}(T_i|X = x_1) \leq \mathbb{P}(T_i|X = x_2)$, where $x_1 < x_2$.

Under Assumptions 1, 2, and 3, the treatment effect is identifiable and is given by the following formula.⁴

$$\begin{aligned} \tau := \mathbb{E}[Y^{(1)} - Y^{(0)}|X = c, C] &= \frac{\lim_{x \downarrow c} \mathbb{E}[Y|X = x] - \lim_{x \uparrow c} \mathbb{E}[Y|X = x]}{\lim_{x \downarrow c} \mathbb{P}[T = 1|X = x] - \lim_{x \uparrow c} \mathbb{P}[T = 1|X = x]} \\ &= \frac{f(c) - \lim_{x \uparrow c} f(x)}{p(c) - \lim_{x \uparrow c} p(x)}. \end{aligned} \quad (1)$$

The denominator in (1) is equal to the compliance rate at the cutoff. It is important to note that although from a theoretical point of view the above formula is valid for any size of the discontinuity in the treatment probability function, in practice, a small compliance rate, arbitrarily close to zero, presents at least two problems. First, if this rate is small, it calls into question the entire design and the meaning of the treatment effect. Second, it makes the estimation of τ unstable, leading to uninformative results. From now on, we assume the following.

Assumption 4. The compliance rate at c , given by

$$j := \left| \lim_{x \downarrow c} \mathbb{P}[T = 1|X = x] - \lim_{x \uparrow c} \mathbb{P}[T = 1|X = x] \right|,$$

is not lower than $\eta \in (0, 1)$.

The precise value of η depends on a specific study and what is deemed a reasonable compliance rate. For medical applications, in the absence of further knowledge, we consider $\eta = 0.2$ a good default value.

3 Bayesian approach to RDD with unknown cutoff

The main challenge of combining cutoff detection with treatment effect estimation lies in the global nature of the former and the local nature of the latter. To detect a jump in the treatment probability function, a broader understanding of the relationship between score and treatment take-up is necessary. Conversely, for treatment effect estimation, the focus shifts to a narrow interval around the cutoff. The data closest to the cutoff are the most valuable; intuitively, the further the score is from the cutoff, the less relevant the corresponding outcome becomes. Our model offers a global fit to data, but it stabilizes the inference near potential cutoffs for higher point estimation precision. In the next subsections we present the treatment and outcome models separately and then discuss how they are integrated.

3.1 Treatment probability

The treatment probability function plays a crucial role in localizing the cutoff. Initially, fitting piece-wise constant functions may appear to be an effective solution for this task. This approach is part of a two-step procedure proposed by Gijbels et al. for changepoint detection in nonparametric regression.¹⁸ In the Bayesian literature, piece-wise constant functions are employed to model abrupt changes in the average value of data distribution.^{19,20} Nonetheless, apart from the cutoff location we also need to estimate the size of the discontinuity in the treatment probability. This value is essential for the design validation and treatment effect estimation, as we see in (1). In many applications, it is not realistic to assume that the probability of receiving treatment is constant on the both sides of the cutoff, hence fitting two constant functions will lead to a heavily biased jump estimator. Moreover, a multi-step procedure would not be advisable for this problem, we give a detailed explanation in Section 3.3.

On the other hand, an overly flexible model is not suitable for the cutoff detection, as the jump in the treatment probability can be well approximated by a steep increase in the underlying function. Furthermore, the treatment take-up is a binary variable. This type of data leads to volatile estimates if no restrictions are put on the underlying probability function p . Fortunately, the function p has a clear interpretation: it is the probability of taking the treatment given a score that is meaningful in the context of the expected outcome. Therefore it is reasonable to assume the following.

Assumption 5. The treatment probability function p is monotone.

For simplicity, but without loss of generality, we assume that p is increasing. Additionally, we expect that the convexity does not change on the each side of the cutoff. Indeed, a change in the convexity can imitate a jump in the treatment probability undermining cutoff detection, and even suggest a flawed study. If we do not know the cutoff, we should be more demanding regarding the treatment allocation mechanism as validation of such design is more difficult. The validation becomes a problem, especially when the compliance rate is relatively low, which is not uncommon in medical applications.^{21,22,23}

Assumption 6. The derivatives of restricted treatment probability functions $p|_{x < c}$, $p|_{x \geq c}$ exist and have no inflection points.

Taking all these aspects into consideration we model the function p on each side of the cutoff

as two increasing connected linear functions (see Figure 1):

$$p(x) = \begin{cases} \alpha_2^L x + \beta_2^L, & x < c - k_t^L, \\ \alpha_1^L x + \beta_1^L, & c - k_t^L \leq x < c, \\ \alpha_1^R x + \beta_1^R, & c \leq x \leq c + k_t^R, \\ \alpha_2^R x + \beta_2^R, & c + k_t^R < x. \end{cases} \quad (2)$$

To ensure that the function p is increasing, takes values between 0 and 1 and has discontinuity of size j at c , where $j \geq \eta$, we need to restrict the coefficients values:

$$\begin{aligned} \alpha_2^L &\in \left[0, \frac{1-j}{c - k_t^L - I_1}\right], & \alpha_1^R &\in \left[0, \frac{1 - \alpha_1^L c - \beta_1^L - j}{k_t^R}\right], \\ \beta_2^L &\in [-\alpha_2^L I_1, 1 - j - \alpha_2^L (c - k_t^L)], & \beta_1^R &= (\alpha_1^L - \alpha_1^R)c + \beta_1^L + j, \\ \alpha_1^L &\in \left[0, \frac{1 - j - \alpha_2^L (c - k_t^L)}{k_t^L}\right], & \alpha_2^R &\in \left[0, \frac{1 - \beta_1^R - (c + k_t^R \alpha_1^R)}{I_2 - c - k_t^R}\right], \\ \beta_1^L &= (c - k_t^L)(\alpha_2^L - \alpha_1^L) + \beta_2^L, & \beta_2^R &= (c + k_t^R)(\alpha_1^R - \alpha_2^R) + \beta_1^R. \end{aligned}$$

Finally, we set conditional uniform priors on each coefficient, for instance $\pi(\beta_2^L | \alpha_2^L) = \mathcal{U}(-\alpha_2^L I_1, 1 - j - \alpha_2^L (c - k_t^L))$. Let $\alpha = (\alpha_1, \alpha_2)$, $\beta = (\beta_1, \beta_2)$, $k_t = (k_t^L, k_t^R)$, then the joint prior distribution is given through the decomposition:

$$\begin{aligned} \pi(\alpha_l, \beta_l, \alpha_r, \beta_r | c, j, k_t) &= \pi(\alpha_2^L | j, k_t) \pi(\beta_2^L | \alpha_2^L, c, j, k_t) \pi(\alpha_1^L | \beta_2^L, \alpha_2^L, c, j, k_t) \dots \\ &\dots \pi(\alpha_2^R | \beta_1^R, \alpha_1^R, \alpha_l, \beta_l, c, j, k_t) \pi(\beta_2^R | \alpha_r, \beta_1^R, \alpha_l, \beta_l, c, j, k_t) \end{aligned}$$

We assume uniform priors on k_t^L and k_t^R :

$$\pi(k_t^L, k_t^R | c) = \mathcal{U}(d_x, c - l_{25}) \mathcal{U}(d_x, u_{25} - c),$$

where d_x is the upper quantile of the radii of balls centered at each X_i containing exactly two other observed values of the score: one below X_i and one above. If the score takes value on a grid, then d_x is the distance between consecutive grid points. This lower bound ensures that there are multiple data points in the window $[c - k_t^L, c + k_t^R]$ and therefore prevents convergence issues. For the same reason, we introduce the bounds l_n and u_n . The value of l_n (u_n) is defined as the minimum (maximum) value such that there are at least n data points with scores below (above) l_n (u_n). We set $n = 25$ as default.

The prior on the cutoff location depends on the specific application. As default we consider a beta prior (or a beta-binomial if X is discrete) scaled and translated to a subset of \mathcal{I} . The most straightforward choice is a uniform distribution with the support in an interval chosen based on expert knowledge or known guidelines. In the case of a weakly informative prior, the distribution support has to be separated from the boundary points I_1 and I_2 to ensure stability of MCMC sampling.

3.2 Outcome model

The next step is the estimation of the potential discontinuity in the outcome function f . Compared to the treatment probability function, this time we opt for a more flexible model. The outcome function does not play a primary role in the cutoff identification and has smaller influence on the stability of the treatment effect estimation. At the same time, we are interested in a point




Figure 1: Illustration of the treatment probability function (2) and the outcome function (3) with the cutoff at 0.

estimate at the cutoff. We need reliable estimates of left and right limits at this point, and the goodness of fit far from it is not important per se. However, it is not an easy task to decrease the influence of distant points in a meaningful way. To illustrate this difficulty, let us consider that the underlying function is linear, then even points that are far from the cutoff carry information relevant to the point estimation at the cutoff. On the other hand, if the underlying function changes rapidly, the points far away are much less informative and can negatively influence the estimation at the cutoff. To tackle this challenge we propose the Local Trimmed Taylor Approximation (LoTTA) model (see Figure 1):

$$f(x) = \begin{cases} \gamma_0^L + \gamma_1^L(x - c), & \text{for } k_f^L < x < c, \\ \gamma_0^L + \gamma_1^L(x - c) + \gamma_2^L(x - c)^2 + \gamma_3^L(x - c)^3, & \text{for } x \leq k_f^L < c, \\ \gamma_0^R + \gamma_1^R(x - c), & \text{for } c \leq x < k_f^R, \\ \gamma_0^R + \gamma_1^R(x - c) + \gamma_2^R(x - c)^2 + \gamma_3^R(x - c)^3, & \text{for } c < k_f^R \leq x. \end{cases} \quad (3)$$

Taking inspiration from local linear regression, we fit linear functions close to the cutoff. In general, global high order polynomial approximations are not recommended in RDD as they may lead to bad estimates close to the cutoff.²⁴ The key element of our model, however, is that the coefficients in the linear part are the same as in the cubic part that is fitted to the data further from the cutoff. This connection helps to stabilize the inference at the cutoff. The big advantage of LoTTA is that it does not require manual adjustments. In particular, the window in which linear parts are fitted is given by model parameters k_f^L and k_f^R . The window selection is a crucial part of local linear regression; if the window bandwidth does not fulfill the theoretical requirements, significant undercoverage can be observed.⁹

We use as a default the cubic function in the tail. For many applications it offers enough flexibility while keeping computing time relatively low. In Section 4 we present diagnostics for the model fit. Naturally, the cubic function is not the only possibility. The most straightforward extension would be to increase the polynomial degree, however, we do not recommend this due to slower convergence and philosophical issues.²⁴ LoTTA can be extended to any function that has Taylor expansion at each point in the domain. Then the linear part is the first order Taylor

approximation of the function in the tail. An example of such extension to inverse logit function is given in Appendix A.

It is important to point out that the function (3) has discontinuity points not only at c but also at k_f^L and k_f^R . Such a modelling choice may not be intuitive at first as in a valid RDD we expect outcomes to follow a regular pattern on each side of the cutoff. Indeed, a big jump in the outcomes near the cutoff would be worrisome and could lead to skewed estimates of the treatment effect. However, the size of the discontinuity in (3) is not arbitrary and diminishes as k_f^L and k_f^R get closer to c . One could think of similar modeling choices, for instance consider polynomial terms of the form $x - k_f^L$ instead of $x - c$. This would eliminate the discontinuities but at the same time change the focus from the point estimate at c to the point estimate at k_f^L . The function is no longer expanded at c - the crucial point in the treatment effect estimation, but at hyperparameters that are not well grounded in the data. In practice, forced continuity at k_f^L and k_f^R can lead to convergence issues and consequently to a bad fit of the posterior outcome function.

As indicated in Section 1 the error term ϵ_x does depend on the score value. Precisely, we assume that $\epsilon_x \sim \mathcal{N}(0, \sigma_{R1})$ for $x \in [c, k_f^R]$ and $\epsilon_x \sim \mathcal{N}(0, \sigma_{R2})$ for $x \in (k_f^R, I_2]$, where $\sigma_{R2} \geq \sigma_{R1}$. Similarly, $\epsilon_x \sim \mathcal{N}(0, \sigma_{L1})$ for $x \in [k_f^L, c]$, and $\epsilon_x \sim \mathcal{N}(0, \sigma_{L2})$ for $x \in [I_1, k_f^L)$, where $\sigma_{L2} \geq \sigma_{L1}$. Allowing the noise to vary more further from the cutoff plays a double role. First, as we approach the boundary values of the score, it is reasonable to expect that the outcomes become more volatile. Second, the increased standard deviation is a signal to the model that those points are of less importance, so the fit there can be compromised.

Now, as our model is fully defined, we consider the prior distributions. For the polynomial coefficients we set diffused hierarchical normal priors:

$$\begin{aligned} \gamma_0^L &\sim \mathcal{N}(0, 100), & \gamma_0^R &\sim \mathcal{N}(0, 100), \\ \gamma_1^L &\sim \mathcal{N}(0, 100), & \gamma_1^R &\sim \mathcal{N}(0, 100), \\ \gamma_2^L &\sim \mathcal{N}(0, 100(c - k_f^L)^{-0.5}), & \gamma_2^R &\sim \mathcal{N}(0, 100(k_f^R - c)^{-0.5}), \\ \gamma_3^L &\sim \mathcal{N}(0, 100(c - k_f^L)^{-0.5}), & \gamma_3^R &\sim \mathcal{N}(0, 100(k_f^R - c)^{-0.5}). \end{aligned}$$

The priors on the quadratic and cubic terms are more dispersed as the linear part get reduced. We do so to take some mass from around 0 and therefore favour longer linear part over longer cubic part with small nonlinear coefficients. If the outcome function is bounded it can also be included in the coefficient priors so that the posterior distribution of the treatment effect is only supported on the possible range of values (see Appendix A).

We assume the following priors on the precisions of the error term:

$$\begin{aligned} \rho_1^r &\sim \chi(7), & \rho_1^l &\sim \chi(7), \\ \rho_2^r &\sim \rho_1^r - \mathcal{U}(0, \rho_1^r), & \rho_2^l &\sim \rho_1^l - \mathcal{U}(0, \rho_1^l). \end{aligned}$$

Similarly as in the treatment model we put uniform priors on k_f^L and k_f^R :

$$k_f^L \sim \mathcal{U}(l_{25}, c - d_x), \quad k_f^R \sim \mathcal{U}(c + d_x, u_{25}).$$

where u_{25} , l_{25} , and d_x are defined as in Subsection 3.1. As before bounding domain of k_f^L and k_f^R is to stabilize the convergence of MCMC algorithm.

On final note: all the above priors are chosen for normalized datasets. Before applying the above model, scores should be divided by their range, and it should be ensured that values of X and Y lie on a similar scale.

3.3 Combining the two models

Now that we have the two main ingredients, the treatment and the outcome model, they need to be combined. There are two main ways to do this: through joint estimation or a cut posterior.²⁵ Joint estimation combines the treatment and outcome models into a single joint likelihood. As a consequence, the posterior distributions of the parameters in these two models are dependent, as they share a common parameter c . The posterior distribution of the cutoff location is influenced both by the treatment allocation and the observed outcomes. Such a dependency between two stages in a model is called model feedback. In the cut posterior approach, the dependence is one-way: the treatment model is fitted first, and the resulting posterior samples of the cutoff location are plugged into the outcome model. Therefore, the posterior distribution of the cutoff location depends only on the treatment take-up data.

In the case of RDD, we strongly advise against the cut posterior approach as it leads to unstable, hard to interpret results. If there is a treatment effect, a slight shift of the cutoff, estimated solely on the binary treatment allocation data, may heavily bias the results (see Appendix C). Identification Assumptions 1 and 2 are linked through a common cutoff location c : the potential discontinuity in the outcome function must occur at the same point as the discontinuity in the treatment probability function. Cutting feedback cuts this important link between the two models, while the joint model naturally exploits this relation. The same rationale applies also to the frequentist approach, in which estimation of the cutoff also should consider the location of the potential discontinuity in the outcome function.¹⁰ If there is no treatment effect, the cut posterior could be beneficial as no additional information about the cutoff location is contained in the outcome data. However, we did not observe negative effects of applying the joint model in this scenario; rather an inherent need of a stronger signal from the data about the jump in the treatment probability function. We move further discussion to Section 5 and Appendix C. Throughout the remainder of this work, we refer to the joint Bayesian model as the LoTTA model.

The above considerations are linked to the ongoing discussion in Bayesian causal inference regarding the role of feedback between design and analysis stages. However, this discussion usually centers on propensity score based models. Those advocating for fully separating the design stage from the analysis stage in these models typically argue based on philosophical considerations²⁶ and better empirical results if the feedback is eliminated, either through a cut posterior¹⁶ or by plugging in the estimator of the propensity score into the outcome model.¹⁴ Interestingly, in the case of RDD, both philosophical and pragmatic arguments are in favor of the joint model.

4 The Bayesian model as a diagnostic and an estimation tool

The Bayesian model can be used both to analyze datasets with unknown cutoff and to validate a cutoff location in a fuzzy RDD with a known or a suspected cutoff. In this section, we present a framework to detect a cutoff (or to diagnose a lack thereof), to check the model fit and to estimate the treatment effect. As an example, we use data from Hlabisa HIV Care and Treatment Programme made available by Cattaneo et al.²⁷ In this study, the score X is the count of CD4 cells per microliter of blood. The intervention is either immediate or deferred access to the antiretroviral therapy (ART). According to the national guidelines at the time, all patients with scores strictly below 350 cells/ μl were eligible for the immediate start of the therapy. However,

in the following analysis we show that a different value was likely used in practice. We encode by $T = 1$ the deferred start of the therapy and by $T = 0$ the immediate start. In this way, we obtain the classic representation of an RDD, as introduced in Section 2. The outcome is retention in care: $Y = 1$ if there is any evidence of retention in care, $Y = 0$ otherwise.

In this section, we discuss general steps of our Bayesian procedure to detect or validate a cutoff. In the next section, we give numerical results and additional details of this particular application. In Appendix B.2 we show how this framework can help in diagnosing a flawed RDD on the chemotherapy dataset previously analyzed by Cattaneo et al.⁵

1. Validate the model assumptions.

1.1. Plot the data. We start by plotting the binned treatment and outcome data (see Figure 2). These plots give an idea of the cutoff location and the size of the potential treatment effect. Additionally, the plot of the treatment take-up indicates whether Assumptions 5 and 6 are plausible. In particular, the plot should have at most two inflection points (due to a possible jump) and present an increasing trend; a decreasing trend requires recoding the data in order to use the model (2) directly.

1.2. Trim the data (optional). In this stage, data can be trimmed if there is some irregular behaviour in the treatment take-up near the boundary points. If the score takes a wide range of values and the units close to the boundary points are edge cases, trimming might be necessary to ensure that assumptions 5 and 6 are justified. We trim ART data to only include score values between 50 and 950 cells/ μl as we notice less regular behaviour and outliers near the boundary points. In the context of RDD, such modest trimming does not influence the reliability of the results. First, based on our prior knowledge and Figure 2 we expect the cutoff to be between 300 and 400 cells/ μl . Second, less than 200 cells/ μl is an indication for AIDS diagnosis, and values between 500 and 1000 cells/ μl are within the normal range.²⁸ Therefore, we are not discarding informative data points regarding the treatment effect at the cutoff.

2. Validate the existence of a cutoff.

2.1. Fit the treatment model. We fit the treatment model (2) separately of the outcome model; this is to detect potential issues within the analysis. If the treatment and the full model lead to different conclusions, it may signal either anomalies in the dataset, a small compliance rate with respect to the amount of data, or misfit of the model. In the ART application we set a uniform prior on the cutoff location between 300 and 400 cells/ μl , and bound the jump size from below by the default value 0.2.

2.2. Fit the full model. Next, we fit the full model. In this application, we use the LoTTA model for binary outcomes. The specification of this model can be found in Appendix A.

2.3. Plot the histograms. We start by comparing the histograms of the posterior distributions of c and j in the treatment and full model. Figure 3 shows that the posterior distributions of the cutoff location are similar and concentrate on the same value. Notably, the joint model assigns even higher mass to 355. This is what we expect if the design is valid, since there appears to be a nonzero treatment effect. Similarly, on Figure 3 we observe that the histograms of the jump size also largely overlap. Importantly, the distribution of j is not skewed towards the lower bound. The left tail is thick, but the mode appears to be around 0.27. Finally, we check that

the posterior distribution of the treatment effect is unimodal. If it is not the case, this may point to multiple cutoffs being identified by the model, or it may signal problems with the model fit.

3. Check the model fit.

3.1. Plot the posterior functions. Each sample from the posterior gives us a treatment probability function and an outcome function. In Figure 4, we plot the pointwise median values along with the pointwise 95% credible intervals of those functions. Underneath them we plot the binned data. We bin the data separately on both sides of the MAP cutoff estimate to visualize the potential jumps.

3.2. Check the stability of the results (optional). If there is a meaningful focus region in the data, then the model can be fitted to it by trimming the data at this region’s boundaries. Then we repeat steps **2.3.** and **3.1.**, and compare the results to the global fit. In ART application we argue that such region is between 200 cells/ μl and 500 cells/ μl (see Step **1.2.**). Figure 4 shows the stability of our results.

4. Report estimates and credible regions. We report the MAP estimates of the treatment effect, the cutoff c , and the compliance rate j with their corresponding 95% highest density intervals.




Figure 2: The binned ART data. We can observe that there is a visible decrease in the immediate access to ART and in the retention in care around 300 and 400 cells/ μl . The official guideline for the cutoff was 350, although as we argue in Section 4 in practice it appears to have been 355.

Further validation of RDD with unknown cutoff In the proceeding part, we focused solely on the cutoff validation, but it is a good practice to check for the covariate balance and score manipulation as well. Cattaneo et al.²⁹ provide a summary of the additional falsification methods. As they all require a fixed cutoff point, we recommend to set it to the MAP estimate of c from the full model and then perform further falsification tests. If there is some anomaly in the region around the MAP estimate, we should be able to detect it without checking multiple points.




Figure 3: The posterior distributions of the cutoff location and compliance rate for the treatment and full LoTTA model. The posterior indicates a cutoff at 355 instead of the cutoff at 350 indicated by study guidelines.

4.1 (Un)known cutoff - ART application

The analysis described in the previous subsection revealed that the official guideline for the immediate ART initiation was not followed by medical practitioners, and that a different cutoff criterion was likely used in practice. The official cutoff of 350 cells/ μl appears to be different from the empirical cutoff of 355 cells/ μl at which the discontinuity in the treatment take-up most probably occurs. While the difference between 355 and 350 may seem not so big, this difference is crucial for correct estimation of the treatment effect. This disparity was so far left unnoticed, even though the data was previously analysed according to the established best practices.^{30,5} Based on the results in Table 1 for LLR at $c = 350$ in the full and trimmed datasets, we speculate that the close proximity of the two points caused an overestimation of the compliance rate at 350 cells/ μl . Consequently, this overestimation led to a validation of the design at an incorrect point. This example demonstrates the need of additional tools that do not aim at falsifying RDD assumptions at a single, given point but take into consideration a broader window of data. This means removing the hidden assumption that a design is either valid at the cutoff given by official guidelines or that it is not valid at all.

In Table 1, we compare the results obtained through LoTTA and LLR. All the results for LLR in this and in the following sections were generated using `rdrobust` package in R.^{9,31} In the case of LLR, we estimate the treatment effect and the compliance rate j both at the given cutoff and at LoTTA's MAP estimate. We consider two datasets: the (almost) full one that includes scores between 50 and 950 cells/ μl , and the trimmed one that includes scores between 200 and 500 cells/ μl . In the full dataset, LLR computed at 350 cells/ μl gives wider confidence intervals and a smaller estimate of the compliance rate, but the results are still fairly similar. The biggest difference occurs for the trimmed dataset. The estimates of LLR both at 355 cells/ μl and particularly at 350 cells/ μl become unstable, visible from the widening of the confidence intervals. However, the problem may not only lie in the cutoff point but also in the nature of the data. Indeed, the trimmed dataset contains 3507 data points, while the full data set contains 6819 data points, and the outcome variable is binary; LLR is not well adjusted to this type of




Figure 4: Median posterior treatment and outcome functions with 95% credible band for ART data. In the upper row we plot the global fit of the LoTTA model. In the bottom row we compare the global fit with the local fit on trimmed data.

outcomes. On the other hand, LoTTA can be easily modified to deal with binary outcomes (see Appendix A), which in turn leads to more stable results. The additional advantage is also achieved through the lower bound on the compliance rate.

5 Simulation results

We perform a series of simulation studies to validate our method. We consider three main scenarios: sharp design with a known cutoff (Scenario 1), and fuzzy design with unknown cutoff and two varying jump sizes in the treatment probability function (Scenarios 2 and 3). We compare our results to local linear regression with robust confidence intervals.⁹ The sharp design is the clearest setup for the comparison as all the methods have access to the cutoff location. For this reason, we include it in our study beside the fuzzy design. The comparison in the fuzzy

Full dataset: $X \in [50, 950]$			
	LLR		LoTTA
	c=350	c=355	
Treatment effect for compliers	-0.64 (-0.99,-0.29)	-0.55 (-0.85,-0.24)	-0.56 (-0.85,-0.38)
Compliance rate	0.19 (0.11,0.28)	0.26 (0.17,0.34)	0.28 (0.2,0.33)
Cutoff location	-	-	355 (354,358)
Trimmed dataset: $X \in [200, 500]$			
	LLR		LoTTA
	c=350	c=355	
Treatment effect for compliers	-0.47 (-1.43,0.48)	-0.47 (-1.12,0.17)	-0.63 (-0.97,-0.31)
Compliance rate	0.09 (-0.05,0.22)	0.19 (0.05,0.33)	0.27 (0.2,0.32)
Cutoff location	-	-	355 (354,358)

Table 1: Reanalysis of ART data. LoTTA refers to the LoTTA model for binary outcomes. For the LLR robust 95% confidence intervals are given in the parenthesis. For LoTTA, MAP estimates are given along with 95% highest density intervals.

design is harder to interpret because there is no other available method that includes cutoff detection or that bounds the discontinuity in the treatment assignment away from 0. Local linear regression with known cutoff in Scenarios 2 and 3 is therefore best viewed as an oracle benchmark to indicate to what extent extra uncertainty is added by having an unknown cutoff.

In each simulation setup, we generate 1000 datasets consisting of 500 data points. Based on simulations previously considered in RDD literature,^{9,13} we sample score values according to $X \sim 2Z - 1$, where $Z \sim \text{beta}(2, 4)$, and we set the cutoff point at 0. Therefore the majority of the data points is located to the left of the cutoff. We set uniform prior on c between -0.8 and 0.2 ; the interval $[-0.8, 0.2]$ contains around 80% to 85% of all score samples. The outcomes were sampled according to $y_i \sim \mu_j(x_i) + \epsilon_i x$, with different mean functions and $\epsilon_i \sim \mathcal{N}(0, 0.1)$. We denote by $g(x) = (1 + \exp(-x))^{-1}$ the inverse logit function and we consider the following functions (see Figure 5).

- A. Cubic: $\mu_A(x) = \mathbb{1}(x < c)[1.8x^3 + 2x^2 + 0.05] + \mathbb{1}(x \geq c)[0.05x - 0.1x^2 + 0.22]$.
- B. Non-polynomial: $\mu_B(x) = \mathbb{1}(x < c)[g(2x) - 0.1] + \mathbb{1}(x \geq c)[0.6(\ln(2x + 1) - 0.15x^2) + 0.20]$.
- C. No treatment effect: $\mu_C(x) = -0.952 - 0.27x + 0.118x^2 + 0.121x^3 + 0.254x^4 - 0.3x^5 - 0.19x^6 - 0.5g(10(x + 1)) + \sin(5x - 2)$.

The first function is a polynomial without a linear part on the left hand side to add difficulty for our model. The second function has an infinite Taylor expansion but a regular shape that we find realistic in the medical context. Finally, the last function corresponds to the scenario of no treatment effect as it is continuous and differentiable in the whole domain. The difference between right and left limit at the cutoff equals to 0.17, -0.2 and 0. We present additional results in Appendix B.1 that include two regularly used functions in the RDD literature, called ‘Lee’ and ‘Ludwig’, and show robustness of LoTTA compared to the global cubic polynomial.

The treatment allocation t_i was sampled according to $\text{ber}(p_j(x_i))$. For the treatment probability function, we considered two increasing functions, with a jumpsize of 0.55 and 0.3.

1. $p_1(x) = \mathbb{1}(x < c)[(x+1)^4/15+0.05] + \mathbb{1}(x \geq c)[g((8.5x-1.5))/10.5-g(1.5)/10.5-1/15+0.65]$.
2. $p_2(x) = \mathbb{1}(x < c)[(x+1)^4/15+0.05] + \mathbb{1}(x \geq c)[g((8.5x-1.5))/10.5-g(1.5)/10.5-1/15+0.35]$.

The jump size of 0.3 is particularly challenging considering that the treatment data is binary and sparse on the right side of the cutoff.




Figure 5: Outcome functions used in simulations: cubic, non-polynomial, no treatment effect.

We summarize the results of the simulations in Table 2 and Table 3. RMSE refers to root mean squared error of the point estimates. Unless stated otherwise, all statistics concern treatment effect estimates.

In the case of the sharp designs, LoTTA and LLR give competitive results. LoTTA tends to have narrower credible intervals, smaller RMSE and better coverage, but slightly higher bias. However, for the fuzzy design the differences become more apparent. LLR presents less stable behaviour, which becomes particularly noticeable for the low compliance rate of 0.3. Unlike LoTTA, LLR does not impose any additional structure on the treatment probability function to decrease the volatility. As the mean values of the statistics are heavily influenced by outliers, in the tables we include the median interval length, and median absolute error and bias for an alternative comparison of the two methods. First, we focus on the bigger jump size. LoTTA has larger median value of interval length. This is expected as there is an additional uncertainty related to the unknown cutoff. Comparing Scenarios 2A and 2B with Scenario 2C, the discrepancy between the median interval lengths of the two methods is smaller - the discontinuity in the outcome function points at the location of the cutoff, increasing precision of the estimates. At the same time LoTTA presents better coverage and smaller estimation errors. Moreover, it identifies better the sign of the treatment effects in Scenario 2A and Scenario 2B. RMSE of the cutoff location suggest that the model tends to correctly identify the cutoff location, with the highest error of 0.04 in Scenario 2C.

In the fuzzy design with a low compliance rate, the instability of LLR becomes more pronounced. In Scenarios 3A and 3B, median credible intervals are relatively long, while the coverage is significantly below the nominal value. The additional structure put on the probability function in LoTTA model becomes particularly advantageous, as it narrows credible intervals while ensuring good coverage. LoTTA concentrates around the true value of c in Scenarios 3A and 3B, but not in 3C. In Scenario 3C, data is not informative enough for the model to find the cutoff, which seems to enlarge treatment effect credible intervals. However, as the treatment effect is 0, misidentification of the cutoff location has little influence on the point estimate of the treatment effect; RMSE in this scenario is similar to the RMSE's of LoTTA in Scenarios 3A and 3B.

Scenario 1: Sharp design						
	Scenario 1A (cubic, $\tau = 0.17$)		Scenario 1B (non-polynomial, $\tau = -0.2$)		Scenario 1C (no treatment effect, $\tau = 0$)	
	LoTTA (KNOWN CUTOFF)	LLR (KNOWN CUTOFF)	LoTTA (KNOWN CUTOFF)	LLR (KNOWN CUTOFF)	LoTTA (KNOWN CUTOFF)	LLR (KNOWN CUTOFF)
RMSE Treatment Effect	0.04	0.05	0.03	0.05	0.03	0.05
Mean Bias	-0.02	-0.00	-0.01	0.00	-0.00	-0.00
Average Credible/Confidence Interval Length	0.19	0.19	0.17	0.19	0.17	0.19
Empirical Coverage	0.97	0.93	0.99	0.92	0.99	0.92
Proportion Correct Sign*	0.98	0.91	0.99	0.96	-	-

Table 2: Simulation results for the sharp design. Both LoTTA and LLR have access to the cutoff location. *‘Correct sign’ refers to intervals identifying the sign of the treatment effect.

Scenario 2: Fuzzy design, $j = 0.55$						
	Scenario 2A (cubic, $\tau = 0.31$)		Scenario 2B (non-polynomial, $\tau = -0.36$)		Scenario 2C (no treatment effect, $\tau = 0$)	
	LoTTA (UNKNOWN CUTOFF)	LLR (KNOWN CUTOFF)	LoTTA (UNKNOWN CUTOFF)	LLR (KNOWN CUTOFF)	LoTTA (UNKNOWN CUTOFF)	LLR (KNOWN CUTOFF)
RMSE Treatment Effect	0.1	9.87	0.08	0.67	0.07	0.13
Mean Bias	-0.05	-0.47	-0.01	0.1	-0.01	-0.00
Median Bias	-0.05	-0.01	-0.01	0.01	-0.01	-0.00
Median Absolute Error Treatment effect	0.06	0.09	0.06	0.1	0.04	0.06
Median Credible/Confidence Interval Length	0.63	0.54	0.58	0.55	0.47	0.32
Mean Credible/Confidence Interval Length	0.65	4.66	0.6	1.12	0.57	0.41
Empirical Coverage	0.98	0.93	0.99	0.92	1	0.96
Proportion Correct Sign*	0.86	0.65	0.96	0.75	-	-
RMSE Cutoff location	0.01	-	0.01	-	0.04	-
RMSE Compliance rate	0.09	0.2	0.09	0.19	0.15	0.19
Scenario 3: Fuzzy design, $j = 0.3$						
	Scenario 3A (cubic, $\tau = 0.57$)		Scenario 3B (non-polynomial, $\tau = -0.67$)		Scenario 3C (no treatment effect, $\tau = 0$)	
	LoTTA (UNKNOWN CUTOFF)	LLR (KNOWN CUTOFF)	LoTTA (UNKNOWN CUTOFF)	LLR (KNOWN CUTOFF)	LoTTA (UNKNOWN CUTOFF)	LLR (KNOWN CUTOFF)
RMSE Treatment Effect	0.21	241.48	0.2	15518.54	0.17	1227.65
Mean Bias	0.01	-9.61	-0.08	495.1	-0.09	-39.52
Median Bias	-0.02	0.02	-0.07	-0.07	-0.08	-0.01
Median Absolute Error Treatment effect	0.11	0.24	0.12	0.26	0.1	0.11
Median Credible/Confidence Interval Length	0.93	1.49	0.86	1.48	1.07	0.65
Average Credible/Confidence Interval Length	1.05	116.77	1.02	4882.73	1.09	894.88
Empirical Coverage	0.99	0.89	0.99	0.89	0.99	0.99
Proportion Correct Sign*	0.71	0.21	0.78	0.3	-	-
RMSE Cutoff location	0.02	-	0.04	-	0.11	-
RMSE Compliance rate	0.07	0.21	0.07	0.2	0.09	0.2

Table 3: Simulation results for the fuzzy design. LLR assumes a known cutoff, while LoTTA estimates it along with the other parameters. *‘Correct sign’ refers to intervals identifying the sign of the treatment effect.

6 Discussion

We demonstrated through a simulation study and a data application that LoTTA performs well in both cutoff detection and treatment effect estimation. The main strength of the model is that it does not require manual tuning; in particular, a window in which linear parts are fitted is treated as a model’s parameter. In addition to being a novel method for analyzing fuzzy RDD’s with unknown cutoffs, LoTTA offers competitive performance in the case of a known cutoff and a sharp design. LoTTA credible intervals have a good coverage and are relatively narrow. In the case of a non-zero treatment effect, they tend to exclude 0 with a higher probability than the LLR confidence intervals. Moreover, even though the default version is based on a cubic function, the underlying idea of first-order Taylor approximation near the cutoff can be translated to other functions as well. An example of an extension to the inverse logit function can be found in Appendix B.1.

However, since there is no one-size-fits-all solution, our method also comes with some limitations. First, it relies on a cubic (or some kind of) parametrization. While our modification of a cubic function is more robust than the standard polynomial (see Appendix B), the model can still result in a poor fit. Thus, it is important to investigate the goodness of fit in an analysis, as proposed in Section 4. Second, since the method is a Bayesian procedure, it requires significantly more computational time. Additionally, our rather complex model may require a long burn-in period, potentially encountering convergence issues. We recommend to use the Bayesian model with relatively small or noisy datasets, datasets with binary outcomes, and naturally the ones with an unknown or a suspected cutoff. Conversely, in the case of large datasets with continuous

outcomes and a known cutoff, local linear regression is a quick and reliable solution.

Seemingly known cutoff

The Bayesian model is not only a tool to analyze RD designs with unknown cutoff: it changes the way we view RD data by treating the cutoff as a model parameter. In particular, it challenges the custom of treating cutoffs given by guidelines as known. It is crucial to acknowledge the difference between a cutoff given by a guideline and an empirical cutoff, so the one at which the jump in the treatment probability occurs. Otherwise, a validation procedure may lead to incorrect conclusions and subsequent misleading results or no results at all if the design gets dismissed. It is difficult to assess how common the disparity between the two cutoffs is, but its occurrence is plausible, given the human factor in the design. In the fuzzy design, some freedom is usually left to decision-makers regarding the choice of an intervention. In medical research, this may result in a larger group of patients receiving a certain treatment than suggested by the guidelines - especially if the treatment is believed to be beneficial. In the case of policy implementation, there might be a delay or haste in the enforcement of a new rule. Possibly, these situations could lead to an invalid RDD. However, they might just as well lead to a valid RDD with a shifted cutoff, especially, since decision-makers usually do not want to stray too far from the rules. LoTTA used as a validation step, may help to detect a shifted cutoff by providing additional information outside the scope of the standard methods.

Replication code

Replication codes for the results in the main manuscript and in the supplementary materials are available in R, and can be found at https://github.com/JuliaMKowalska/RDD_unknown_cutoff.

7 Acknowledgements

This work is part of the project funded by the Dutch Research Council (NWO) under the Open Competition Domain Science-M programme (agreement No. OCENW.M20.190).

References

- ¹ DL Thistlethwaite and DT Campbell. Regression-discontinuity analysis: An alternative to the ex post facto experiment. *Journal of Educational Psychology*, 51(6):309–317, 1960.
- ² E Moscoe, J Bor, and T Bärnighausen. Regression discontinuity designs are underutilized in medicine, epidemiology, and public health: a review of current and best practice. *Journal of Clinical Epidemiology*, 68(2):122–133, 2015.
- ³ MH Hilton, P Craig, H Thomson, M Campbell, and L Moore. Regression discontinuity designs in health: A systematic review. *Epidemiology*, 32(1):87–93, 2021.
- ⁴ GW Imbens and T Lemieux. Regression discontinuity designs: A guide to practice. *Journal of Econometrics*, 142:615–635, 2008.
- ⁵ MD Cattaneo, L Keele, and R Titiunik. A guide to regression discontinuity designs in medical applications. *Statistics in Medicine*, 42(24):4484–4513, 2023.
- ⁶ DS Lee. Randomized experiments from non-random selection in u.s. house elections. *Journal of Econometrics*, 142(2):675–697, 2008.
- ⁷ LN van Steenberg, GA Denissen, A Spooren, SM van Rooden, FJ van Oosterhout, JW Morrenhof, and RGHH Nelissen. More than 95% completeness of reported procedures in the population-based dutch arthroplasty register. *Acta Orthopaedica*, 4(86):498–505, 2015.
- ⁸ E Zaniewski, E Brazier, CHD Ostinelli, R Wood, M Osler, KG Technau, JJ van Oosterhout, N Maxwell, J van Dijk, H Prozesky, MP Fox, J Bor, D Nash, and M Egger. Regression discontinuity analysis demonstrated varied effect of treat-all on cd4 testing among southern african countries. *Journal of Clinical Epidemiology*, 140:101–110, 2021.
- ⁹ S Calonico, MD Cattaneo, and R Titiunik. Robust nonparametric confidence intervals for regression-discontinuity designs. *Econometrica*, 82(6):2295–2326, 2014.
- ¹⁰ J Porter and P Yu. Regression discontinuity designs with unknown discontinuity points: Testing and estimation. *Journal of Econometrics*, 189(1):132–147, 2014.
- ¹¹ S Geneletti, AG O’Keeffe, LD Sharples, S Richardson, and G Baio. Bayesian regression discontinuity designs: Incorporating clinical knowledge in the causal analysis of primary care data. *Statistics in Medicine*, 34(15):2334–2352, 2015.
- ¹² S Chib, E Greenberg, and A Simoni. Nonparametric bayes analysis of the sharp and fuzzy regression discontinuity designs. *Econometric Theory*, 39(3):481–533, 2023.
- ¹³ Z Branson, M Rischard, L Bornn, and LW Miratrix. A nonparametric bayesian methodology for regression discontinuity designs. *Journal of Statistical Planning and Inference*, 202:14–30, 2019.
- ¹⁴ CM Zigler, K Watts, RW Yeh, Y Wang, BA Coull, and F Dominici. Model feedback in bayesian propensity score estimation. *Biometrics*, 69(1):263–273, 2013.
- ¹⁵ JM Robins, MA Hernán, and LA Wasserman. Discussion of “on bayesian estimation of marginal structural models”. *Biometrics*, 2(71):283–296, 2015.

- ¹⁶ LC McCandless, IJ Douglas, SJ Evans, and L Smeeth. Cutting feedback in bayesian regression adjustment for the propensity score. *The International Journal of Biostatistics*, 2(6), 2010.
- ¹⁷ MA Hernán and JM Robins. *Causal Inference: What If*. CRC Press, 2020.
- ¹⁸ I Gijbels and AC Goderniaux. Bandwidth selection for changepoint estimation in nonparametric regression. *Technometrics*, 46(1):76–86, 2004.
- ¹⁹ D Barry and JA Hartigan. A bayesian analysis for change point problems. *Journal of the American Statistical Association*, 88(421):309–319, 1993.
- ²⁰ YC Yao. Estimation of a noisy discrete-time step function: Bayes and empirical bayes approaches. *Annals of Statistics*, 4(12):1434–1447, 1984.
- ²¹ MC Odden, A Zhang, N Jawadekar, A Tan, AE Moran, MM Glymour, C Brayne, A Zeki Al Hazzouri, and S Calonico. Regression discontinuity design to evaluate the effect of statins on myocardial infarction in electronic health records. *European Journal of Epidemiology*, 38:393–402, 2023.
- ²² A Mody, I Sikazwe, AS Namwase, M Wa Mwanza, T Savory, A Mwila, L Mulenga, ME Herce, K Mweebo, P Somwe, I Eshun-Wilson, K Sikombe, LK Beres, J Pry, CB Holmes, C Bolton-Moore, and EH Geng. Effects of implementing universal and rapid hiv treatment on initiation of antiretroviral therapy and retention in care in zambia: a natural experiment using regression discontinuity. *Lancet HIV*, 8(12):755–765, 2021.
- ²³ ML Anderson, C Dobkin, and D Gorry. The effect of influenza vaccination for the elderly on hospitalization and mortality: An observational study with a regression discontinuity design. *Annals of Internal Medicine*, 172(7):445–452, 2020.
- ²⁴ A Gelman and G Imbens. Why high-order polynomials should not be used in regression discontinuity designs. *Journal of Business & Economic Statistics*, 3(37):447–456, 2019.
- ²⁵ PE Jacob, LM Murray, CC Holmes, and CP Robert. Better together? statistical learning in models made of modules. *arXiv preprint arXiv:1708.08719*, 2017.
- ²⁶ DB Rubin. For objective causal inference, design trumps analysis. *The Annals of Applied Statistics*, 3(2):808–840, 2008.
- ²⁷ Ckt_2023_sim-art. https://github.com/rdpackages-replication/CKT_2023_SIM. Accessed: 2023-10-25.
- ²⁸ SAB Garcia and N Guzman. Acquired immune deficiency syndrome cd4 count. <https://www.ncbi.nlm.nih.gov/books/NBK513289/>, 2020. Available online at <https://www.ncbi.nlm.nih.gov/books/NBK513289/>.
- ²⁹ MD Cattaneo, N Idrobo, and R Titiunik. *A Practical Introduction to Regression Discontinuity Designs: Foundations*. Elements in Quantitative and Computational Methods for the Social Sciences. Cambridge University Press, 2020.
- ³⁰ J Bor, MP Fox, S Rosen, A Venkataramani, F Tanser, D Pillay, and T Bärnighausen. Treatment eligibility and retention in clinical hiv care: A regression discontinuity study in south africa. *PLoS Medicine*, 14(11), 2017.

³¹ Sebastian Calonico, Matias D. Cattaneo, and Rocío Titiunik. rdrobust: An R Package for Robust Nonparametric Inference in Regression-Discontinuity Designs. *The R Journal*, 7(1):38–51, 2015.

³² Ckt_2023_chemo. https://github.com/rpackages-replication/CKT_2023_SIM/blob/master/CKT_2023_Chemo.dta. Accessed: 2023-11-24.

A Extensions of the outcome model to bounded and binary outcomes

In many applications outcomes take values between 0 and 1, and consequently the treatment effect for compliers takes values between -1 and 1 . In general, if outcome function is bounded $a \leq f(x) \leq b$ for $x \in \mathcal{I}$, then the treatment effect τ takes values in the interval $[a - b, b - a]$ and therefore $j \geq \frac{|\gamma_0^R - \gamma_0^L|}{b - a}$, assuming that $j > 0$. This knowledge can be included in the joint model through a suitable hierarchical priors on j , γ_0^L and γ_0^R :

$$\begin{aligned}\gamma_0^L &\sim \mathcal{U}(a, b), \\ \gamma_0^R &\sim \mathcal{U}(a, b), \\ j &\sim \mathcal{U}(\max\{\eta, |\gamma_0^R - \gamma_0^L|(b - a)^{-1}\}, 1).\end{aligned}$$

If the outcomes take binary values, the model has to be modified, so that all values of f are between 0 and 1. We ensure it through inverse logit link function in the tail, and bounded linear function near the cutoff.

$$f^{binary}(x) = \begin{cases} \gamma_0^L + \gamma_1^L(x - c), & \text{for } k_f^L < x < c. \\ \left(1 + e^{-(\gamma_0^L + \gamma_1^L(x - c) + \gamma_2^L(x - c)^2 + \gamma_3^L(x - c)^3)}\right)^{-1}, & \text{for } x \leq k_f^L < c. \\ \gamma_0^R + \gamma_1^R(x - c), & \text{for } c \leq x < k_f^R. \\ \left(1 + e^{-(\gamma_0^R + \gamma_1^R(x - c) + \gamma_2^R(x - c)^2 + \gamma_3^R(x - c)^3)}\right)^{-1}, & \text{for } c < k_f^R \leq x. \end{cases} \quad (4)$$

In this model, the coefficients $\gamma_0^L, \gamma_1^L, \gamma_0^R, \gamma_1^R$ are chosen so that $\gamma_0^L + \gamma_1^L(x - c)$ and $\gamma_0^R + \gamma_1^R(x - c)$ are the first order Taylor approximation at c of $(1 + \exp[-(\gamma_0^L + \gamma_1^L(x - c) + \gamma_2^L(x - c)^2 + \gamma_3^L(x - c)^3)])^{-1}$ and $(1 + \exp[-(\gamma_0^R + \gamma_1^R(x - c) + \gamma_2^R(x - c)^2 + \gamma_3^R(x - c)^3)])^{-1}$, respectively. In particular, they are given by

$$\begin{aligned}\gamma_0^L &= \log \frac{\gamma_0^L}{1 - \gamma_0^L}, & \gamma_0^R &= \log \frac{\gamma_0^R}{1 - \gamma_0^R}, \\ \gamma_1^L &= \frac{\gamma_1^L}{\gamma_0^L(1 - \gamma_0^L)}, & \gamma_1^R &= \frac{\gamma_1^R}{\gamma_0^R(1 - \gamma_0^R)}.\end{aligned}$$

The priors stay the same as for model 3, except for the linear coefficients.

$$\begin{aligned}\gamma_0^L &\sim \mathcal{U}(0, 1), & \gamma_0^R &\sim \mathcal{U}(0, 1), \\ \gamma_1^L &\sim \mathcal{U}\left(\frac{1 - \epsilon - \gamma_0^L}{k_f^L - c}, \frac{\epsilon - \gamma_0^L}{k_f^L - c}\right), & \gamma_1^R &\sim \mathcal{U}\left(\frac{\epsilon - \gamma_0^R}{k_f^R - c}, \frac{1 - \epsilon - \gamma_0^R}{k_f^R - c}\right).\end{aligned}$$

B Additional Results

B.1 Lee & Ludwig functions

The functions that are commonly used to compare methods in RDD are Lee and Ludwig functions.

- Lee function: $\mu_{Lee}(x) = \mathbb{1}(x < c)[0.48 + 1.27x + 7.18x^2 + 20.21x^3 + 21.54x^4 + 7.33x^5] + \mathbb{1}(x \geq c)[0.52 + 0.84x - 3x^2 + 7.99x^3 - 9.01x^4 + 3.56x^5]$.

Sharp design						
	Lee ($\tau = 0.04$)			Ludwig ($\tau = -3.45$)		
	LoTTA (KNOWN CUTOFF)	LLR (KNOWN CUTOFF)	Cubic (KNOWN CUTOFF)	LoTTA (KNOWN CUTOFF)	LLR (KNOWN CUTOFF)	Cubic (KNOWN CUTOFF)
RMSE Treatment Effect	0.05	0.07	0.1	0.08	0.09	0.1
Average Credible / Confidence Interval Length	0.21	0.25	0.23	0.26	0.34	0.23
Empirical Coverage	0.97	0.91	0.73	0.93	0.93	0.74
Proportion Correct Sign*	0.18	0.16	0.57	1	1	1
Mean Bias	-0.02	-0.01	-0.08	-0.04	-0.00	-0.08

Table 4: Comparison of LoTTA, LLR, and cubic regression for Lee and Ludwig functions. * ‘Correct sign’ refers to intervals identifying the sign of the treatment effect.

- Ludwig function: $\mu_{Lud}(x) = \mathbb{1}(x < c)[3.71 + 2.3x + 3.28x^2 + 1.45x^3 + 0.23x^4 + 0.03x^5] + \mathbb{1}(x \geq c)[0.26 + 18.49x - 54.81x^2 + 74.3x^3 - 45.02x^4 + 9.83x^5]$.

Due to their shapes, they are challenging cases (see Figure 6). In this section we compare LLR, LoTTA and Bayesian cubic regression on 1000 simulated datasets. Cubic regression refers to fitting independently two cubic polynomials on each side of the cutoff. For these simulations, we set error standard deviation to 0.1295, so our results can be compared to other results in the RDD literature.^{13,9} In Table 4, we see that LoTTA is more robust than the classic cubic model. The biggest pitfall of the cubic model is the low coverage, which is significantly below the nominal value. On the other hand, LoTTA and LLR both perform well. LoTTA is better in terms of the empirical coverage, RMSE and intervals length, whereas LLR offers smaller bias.




Figure 6: Outcome functions used in simulations: Lee and Ludwig.

B.2 Chemotherapy dataset

Cattaneo et al. in their paper *A Guide to Regression Discontinuity Designs in Medical Applications*⁵ give an example of a faulty regression discontinuity design. The data the authors provide,³² contains information about oncoscore of patients, chemotherapy uptake, and cancer re-occurrence. A common guideline is to give chemotherapy to patients with oncoscore equal or higher than 26. This creates a potential opportunity to estimate the effect of the chemotherapy through a fuzzy RDD. However, the authors’ analysis shows that the compliance rate is too low and crucial covariates are not balanced near the cutoff. Therefore, the design is not valid. We can come to the same conclusion through the Bayesian analysis as well. We start by plotting the treatment




Figure 7: Binned data of chemotherapy take-up and cancer recurrence. There is visible increase in the chemotherapy take-up in the interval $[20, 30]$.

allocation data, see Figure 7. We observe that the treatment take-up increases in the interval between the scores 20 and 30. We set uniform prior on the cutoff location between 20 and 30, and we fit the treatment and the full model with lower bound of $\eta = 0.2$ on the compliance rate. The histogram shows that posterior concentrates at two neighbouring points 26 and 25 and jump in the treatment probability function leans towards the lower bound, see Figure 8. Such posterior distributions of c and j suggest a steep increase instead of a jump. Next, we lower the bound on the compliance rate to 0.1. Again, the posterior concentrates around the same points, but this time the posterior of the compliance rate has a visible peak around 0.19. Nonetheless, there is still considerable mass near 0.1. Even though, for both choices of η , the full model put the highest mass on the suspected cutoff of 26, the neighboring point also have significant probability of being a cutoff point. We conclude that the design is not valid.

C Cut posterior

In this section, we compare the joint posterior with the cut posterior on two simulated datasets of 500 data points with and without treatment effect. The two datasets share the same treatment data, but have different outcome data. The treatment data was generated according to the function p_2 given in Section 5 that corresponds to the compliance rate of 0.3. In the first dataset outcomes were generated according to the function μ_B with the discontinuity at 0 of size -0.2 . In the second dataset, outcomes were generated according to the continuous function μ_C . In our example, the treatment take-up data is misleading regarding the cutoff location. In such cases the cut posterior approach may produce unreliable results (see Figure 9). In the first dataset, the cut posterior skews the treatment effect towards 0 as a result of the shifted cutoff distribution estimated in the first stage. On the other hand, the joint model exploits the continuous outcome data to localize the cutoff and estimates the negative treatment effect. In the second dataset, as the underlying function is continuous, there is no additional information in the outcome data to correct the cutoff estimation (see Figure 10). However, if there is no treatment effect, correct estimation of the cutoff is of lesser importance. In principle, approximated discontinuity size at




Figure 8: Posterior distributions of the cutoff location and compliance rate of the chemotherapy take-up. The posterior of the full model puts the highest mass on the suspected cutoff of 26, but the neighboring point also have high posterior probability of being a cutoff point. Together with posterior distribution skewed to the left they suggest invalid RDD.




Figure 9: Histogram of 1000 posterior samples of the cutoff location and treatment effect from a single dataset with negative treatment effect. The true values are marked with dotted lines. Low compliance rate of 0.3 and little data lead to misleading results regarding the cutoff location if only treatment allocation data is considered. Consequently, in the cut posterior approach, the error is propagated to the treatment effect estimation.

any point in the outcome function should be close to 0.

D Algorithm implementation

We program our models in JAGS, which makes it easy for other users to modify. We approximate the discontinuities at k_f^L and k_f^R in the outcome function with a sigmoid function.

$$\tilde{f}(x) = \begin{cases} \gamma_0^L + \gamma_1^L(x - c) + g(100(k_f^L - x))(\gamma_2^L(x - c)^2 + \gamma_3^L(x - c)^3), & \text{for } x < c, \\ \gamma_0^R + \gamma_1^R(x - c) + g(100(x - k_f^R))(\gamma_2^R(x - c)^2 + \gamma_3^R(x - c)^3), & \text{for } c \leq x, \end{cases}$$

where $g(x)$ is inverse logit function. It is important to notice that the order in which variables are introduced in the JAGS code may influence the convergence speed, and therefore the overall quality of the posterior samples. We initiate the MCMC chains based on the given data. In particular, in the preliminary step we fit two constant functions to the treatment data to get a rough estimate of the cutoff location. Then, randomly selected posterior samples are used as initial values of the cutoff c .

In terms of computational time, we obtained the following results (Apple M2 Pro, 16 GB RAM, macOS Sonoma 14.2.1). ART full dataset (6819 data points, 4 parallel chains, burnin: 40000, samples: 25000): 13 h 11 min; ART trimmed dataset (3507 data points, 4 parallel chains, burnin: 40000, samples: 25000): 5 h 30 min; chemotherapy dataset (1923 data points, 4 parallel chains, burnin: 30000, sample: 25000): 39 min; single simulation for fuzzy design with unknown cutoff (500 data points, 4 parallel chains, burnin: 30000, sample: 25000): 4 min; single simulation for sharp design (500 data points, 4 parallel chains, burnin: 30000, sample: 25000): 1 min.




Figure 10: Histogram of 1000 posterior samples of the cutoff location and treatment effect from a single dataset with no treatment effect. The true values are marked with dotted lines. In case of no treatment effect the joint model does not have additional information to correct the cutoff location.